Premium
Oral cyclosporine A treatment is feasible after myeloablative conditioning in allogeneic hematopoietic stem cell transplantation
Author(s) -
Nygaard M.,
Hovgaard D.,
Schjødt I. M.,
Andersen N. S.,
Vindeløv L.,
Sengeløv H.
Publication year - 2015
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12266
Subject(s) - medicine , transplantation , hematopoietic stem cell transplantation , incidence (geometry) , stem cell , oral administration , surgery , haematopoiesis , gastroenterology , biology , physics , optics , genetics
Summary What is known and objective The target level and route of administration of cyclosporine A (CsA) differ between transplantation centres. It is unclear whether oral CsA is sufficient to maintain target level of CsA. Case summary We retrospectively analysed data from 48 adult patients, who underwent myeloablative hematopoietic stem cell transplantation. Twenty‐one patients (44%) tolerated CsA orally throughout the transplantation period without increased incidence of acute graft versus host disease( aGVHD ). Low concentration of CsA in week 2 was associated with increased incidence of aGVHD . What is new and conclusion Oral administration of CsA is safe, less time‐consuming and economically advantageous. Close monitoring of CsA concentration is important.